Editor’s Note: A few weeks ago, a Type 1 diabetes patient authored a blog post about why she didn’t want to switch to Medtronic’s MiniMed 670G billed as the industry’s first hybrid closed-loop insulin ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The MiniMed 670G hybrid closed-loop insulin delivery system (Medtronic) offers the potential for improved blood glucose control for people with type 1 diabetes, but clinicians should anticipate the ...

The Food and Drug Administration surprised—and pleased—the diabetes medical community this year when they approved a new, high-tech insulin delivery system for Type I diabetics six months sooner than ...

International Diabetes Federation estimates about 415 million people worldwide suffer from diabetes, a number that is expected to increase. Of these, 5% - 10% have Type I diabetes. According to a ...

Results show how the hybrid closed loop system reduced glycemic variability, which leads to fewer long-term complications from type 1 disease. The trial reports what had been announced already: the ...

Medtronic plc, the global leader in medical technology, announced that the US Food and Drug Administration (FDA) has approved the use of the MiniMed 670G system in patients with type 1 diabetes seven ...

Aggregated real-world outcome data collected from thousands of Medtronic MiniMed 670G users indicate that patients on the system spend an average 71% of their time within an optimal glycemic range.

Medtronic plc.'s MDT Diabetes Management segment is dominating the headlines of late. Following the company’s receipt of the CE Mark approval for its advanced continuous glucose monitoring (CGM) ...